title: Effect of acute and chronic stress restraint on amphetamine-associated place preference: involvement of dopamine D(1) and D(2) receptors.
abstract: The purpose of this study was to determine the D-amphetamine (1.0, 1. 5 and 2 mg/kg i.p.)-induced place preference in rats pre-exposed to acute or chronic restraint stress, using the conditioned place preference model. We also studied the involvement of opioid and dopamine mechanisms in the acute restraint stress-induced increase of D-amphetamine-induced place preference. A single restraint session (2 h) but not chronic restraint (2 h/day for 7 days) leading to adaptation to the stressor, enhanced the D-amphetamine-induced place preference. This enhancing effect was prevented by haloperidol administration (0.4 mg/kg i.p.), (+/-)-sulpiride (60 mg/kg i.p.) or R(+)-SCH-23390 hydrochloride (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine hydrochloride, 30 microg/kg i.p.) 10-20 min prior to the acute restraint session. However, naltrexone pretreatment (1 or 2 mg/kg i.p.) failed to prevent the acute restraint-induced enhancement of D-amphetamine-induced place preference. These results suggest that: (1) the enhancement of D-amphetamine-induced place preference occurred after a single restraint stress but not following chronic restraint stress, (2) the stimulation of both dopamine D(1) and D(2) receptors is necessary for the development of single restraint stress-induced enhancement of D-amphetamine-induced place preference and (3) apparently, an opioid system is not involved in this acute restraint-induced effect.
authors.affiliation: Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad universitaria, 5000, Córdoba, Argentina.
authors.forename: N
authors.initials: N
authors.lastname: Capriles
authors.forename: L M
authors.initials: LM
authors.lastname: Cancela
mesh_terms: D000208:Acute Disease; D000223:Adaptation, Psychological / Q000187:drug effects; D000661:Amphetamine / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D002908:Chronic Disease; D003213:Conditioning, Psychological; D015259:Dopamine Agents / Q000494:pharmacology; D008297:Male; D009294:Narcotics / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012149:Restraint, Physical; D013312:Stress, Physiological / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology*
chemical_list: D015259:Dopamine Agents; D009294:Narcotics; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D000661:Amphetamine